DrugPatentWatch Database Preview
ADVIL ALLERGY SINUS Drug Profile
» See Plans and Pricing
When do Advil Allergy Sinus patents expire, and what generic alternatives are available?
Advil Allergy Sinus is a drug marketed by Glaxosmithkline and is included in one NDA. There is one patent protecting this drug.
This drug has thirty-four patent family members in eighteen countries.
The generic ingredient in ADVIL ALLERGY SINUS is chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride. There are twenty-nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride profile page.
US ANDA Litigation and Generic Entry Outlook for Advil Allergy Sinus
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 28, 2027. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for ADVIL ALLERGY SINUS
| International Patents: | 34 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in ADVIL ALLERGY SINUS? | ADVIL ALLERGY SINUS excipients list |
| DailyMed Link: | ADVIL ALLERGY SINUS at DailyMed |
Generic Entry Opportunity Date for ADVIL ALLERGY SINUS
Generic Entry Date for ADVIL ALLERGY SINUS*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for ADVIL ALLERGY SINUS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | ADVIL ALLERGY SINUS | chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride | TABLET;ORAL | 021441-001 | Dec 19, 2002 | OTC | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ADVIL ALLERGY SINUS
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Hong Kong | 1166602 | Start Trial |
| Chile | 2003002653 | Start Trial |
| Hong Kong | 1078494 | Start Trial |
| Taiwan | I313598 | Start Trial |
| Japan | 5241228 | Start Trial |
| China | 1726035 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
